UNSPSC 51351516: Anagestone

This classification denotes a therapeutic progestin with the molecular formula C22H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8FB38IU3G, chemically known as 17-hydroxy-6.alpha.-methylpregn-4-en-20-one but generally known as anagestone, which bears US NIH Compound Identifier 160650. European Medicines Agency schedules Anagestone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05498MIG. Most nations schedule anagestone under HS 29372300 and SITC 54153.

As of Q4 2014, ANAGESTONE remains the US FDA Preferred Term for this commodity. Anagestone bears US NLM identifiers UMLS ID C0051808 and NCI Concept Code C79752. SMILES: CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CCCC4)C.

UNSPSC 51351516 Anagestone, a Commodity code, covers generic pharmaceutical products and over-the-counter offerings that state and local health agencies and facilities procure through cooperative purchasing arrangements and direct supply agreements. The work involves supplying manufacturers' generic multi-source pharmaceuticals and OTC products meeting FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) certification requirements, with products distributed through authorized pharmaceutical wholesalers to participating government facilities. Issuing bodies under this code include state health departments and multistate cooperative purchasing alliances administering pharmaceutical procurement on behalf of multiple participating jurisdictions and member agencies.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving Minnesota, Oregon, and other participating states and localities. The solicitation closes March 26, 2026 and requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contract awards effective July 1, 2026 and a two-year initial term. Evaluation weights 75 percent on price competitiveness, with the remaining 25 percent distributed across fixed pricing structure (10 percent), compliance with administrative data format and EDI capability (10 percent combined), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and maintain contractual relationships with at least two of the three authorized wholesalers.